GlaxoSmithKline

GSK says its COVID antibody therapy works against Omicron. Here’s what other drugmakers say about their treatments

CureVac scraps its first-generation COVID-19 vaccine candidate, shares tumble

Glaxo reaches $2.2 billion deal with Alector to develop drug targeting Alzheimer’s, Parkinson’s

GlaxoSmithKline gets rid of Trump’s vaccine adviser Slaoui for sexual harassment

Promising COVID-19 antibody therapy significantly reduces risk of hospitalization, death